<DOC>
	<DOCNO>NCT01898117</DOCNO>
	<brief_summary>Triple negative breast cancer ( TNBC ) difficult treat molecular subtype poor survival . TNBC divide least two molecular entity ; BRCA-like non-BRCA-like . In trial would like investigate whether molecular subgroup exists within TNBCs derive benefit bevacizumab add first line chemotherapy .</brief_summary>
	<brief_title>Triple-B Study ; Carboplatin-cyclophosphamide Versus Paclitaxel With Without Bevacizumab First-line Treatment Advanced Triple Negative Breast Cancer</brief_title>
	<detailed_description>In preclinical study addition bevacizumab chemotherapy improve drug access tumor . In human , bevacizumab monotherapy normalizes tumor vascularization . It presently unknown molecular subtype would derive progression free survival ( PFS ) benefit addition bevacizumab first line chemotherapy . There indication patient high VEFGA and/or VEFGR-2 plasma level derive benefit . There indication TNBC BRCA-like sensitive bifunctional alkylating platinum agent non-BRCA-like TNBCs , relatively resistant taxanes . Consequently , TNBCs general derive substantial benefit taxanes , anticipate non-BRCA-like TNBCs exquisitely sensitive taxanes . Bevacizumab paclitaxel synergistic preclinical model . Therefore anticipate bevacizumab add paclitaxel confers substantial progression-free survival benefit non-BRCA-like patient . We would like test hypothesis prospective clinical trial .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm triple negative breast cancer Histological confirmation triple negative breast cancer metastatic lesion recommend Histological cytological confirmation metastatic breast cancer require case normal CA 15.3 level No previous cytotoxic therapy metastatic disease Diseasefree interval least 12 month completion adjuvant paclitaxel platinum compound therapy Diseasefree interval least 6months completion adjuvant docetaxel Measurable disease accord RECIST Plasma baseline sample send NKIAVL sVEGFR level test Primary tumor metastasis tissue send NKIAVL BRCAlike test WHO performance status 0 1 Adequate bone marrow function : neutrophil ≥ 1.5 x 10E9 cells/l , platelet ≥100 x 10E9 cells/l , Hb ≥ 6.2 mmol/l . Normal liver function : bilirubin &lt; 1.5 x upper limit normal range ( ULN ) ; alkaline phosphatase &lt; 2.5 x ULN ( &lt; 5 x ULN case liver metastasis , &lt; 7 x ULN case bone metastasis ) ; transaminase ( ASAT/ALAT ) &lt; 2.5 x ULN ( &lt; 5 x ULN case liver metastasis ) . Normal renal function : calculate ( CockcroftGault ) measure creatinine clearance &gt; 50 mL/min Urine dipstick proteinuria &lt; 2+ . Patients &gt; 2+ proteinuria dipstick urinalysis baseline undergo 24hours urine collection must demonstrate ≤1 g protein/24hr . INR &lt; 1.5 APTT normal , unless patient stable anticoagulant treatment least two week low molecular weight heparin coumarin , INR within target range ( usually 2 3 ) allow . Written inform consent Receptor conversion hormone receptor positive ( defined &gt; = 1 % positive ER PgR tumor cell ) HER2 positive Another cancer except basalcell carcinoma skin situ cervical cancer within previous 5 year Other antitumor therapy within previous 21 day Known CNS disease except treated brain metastasis . Uncontrolled serious medical psychiatric illness Preexisting peripheral neuropathy &gt; grade 1 ( NCICTC AE ( version 4.03 ) ) inclusion History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month randomization An infection require parenteral antibiotic Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization anticipation need major surgical procedure course study Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis within 6 month prior randomization ) Non heal wound non heal fracture Arterial venous thrombosis ≤ 12 month prior registration Inadequate control hypertension ( systolic &gt; 140 mm Hg and/or diastolic &gt; 90 mm Hg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association Class II great congestive heart failure . LVEF MUGA ultrasound must ≥ 50 % perform within 4 week prior randomization cardiac failure suspect . History myocardial infarction unstable angina within 6 month prior randomization History stroke transient ischemic attack within 6 month prior randomization Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) History hemoptysis within 1 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Triple negative</keyword>
	<keyword>Metastatic</keyword>
</DOC>